From CNBC: 2024-07-11 10:53:34

Pfizer is advancing a once-daily version of its weight loss pill, danuglipron, after positive early-stage study results. The company plans more trials to determine the ideal dose of the drug. Pfizer aims to compete in the $100 billion GLP-1 market, despite past setbacks with other obesity medications.

Pfizer discontinued a twice-daily version of danuglipron due to patient tolerability issues in a mid-stage study. The company’s struggle to break into the market has affected investor confidence. Pfizer has other obesity drugs in development and believes GLP-1s have untapped potential in treating obesity.

Developing a once-daily version of danuglipron puts Pfizer in competition with Novo Nordisk and Eli Lilly’s injections for weight loss and diabetes. Oral versions may help address supply shortages. Pfizer is open to acquisitions or partnerships with smaller obesity drugmakers.

Dr. Mikael Dolsten’s departure from Pfizer has spurred the search for his successor. He played a crucial role in developing the company’s Covid vaccine. Pfizer remains committed to the obesity market and is exploring licensing deals or early-stage weight loss drugs.



Read more at CNBC: Pfizer weight loss pill moves forward as once-daily version